Pharma & Healthcare

Global Tumor Immunity PD-1 Inhibitors Market Research Report 2023

According to HengCe’s new survey, global Tumor Immunity PD-1 Inhibitors market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The development of tumor immunity PD-1 inhibitors is mainly affected by the following driving factors:
Market demand: As the number of cancer patients continues to increase around the world, the demand for innovative drugs in the cancer treatment market is also growing. As a new type of immunotherapy drug, PD-1 inhibitors have huge market potential.
Scientific and technological innovation: The development of immunotherapy provides technical support for the research and development of PD-1 inhibitors. With a deeper understanding of tumor immune mechanisms, scientists continue to explore how to use the PD-1 signaling pathway to regulate immune responses and develop more effective PD-1 inhibitors.
Policy support: Government support and encouragement policies for the pharmaceutical industry provide a good environment for the development and marketing of PD-1 inhibitors. For example, agencies such as the U.S. Food and Drug Administration (FDA) have provided a fast track for the approval of innovative drugs, accelerating the launch of PD-1 inhibitors.
Capital investment: The research and development of PD-1 inhibitors requires a large amount of financial support, including clinical trials, production and marketing. Large pharmaceutical companies and venture capital institutions are increasingly investing in the field of PD-1 inhibitors, providing financial guarantee for the development of this field.
Clinical needs: Traditional chemotherapy, radiotherapy and other treatment methods have serious side effects on cancer patients, and there are drug resistance problems. As a new type of immunotherapy drug, PD-1 inhibitors have low toxicity and good tolerability, which can meet clinical needs and improve patients' survival rate and quality of life.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tumor Immunity PD-1 Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Novartis
Sumitomo Dainippon Pharma
Genentech (Roche)
AstraZeneca
Pfizer
GSK
Regeneron Pharmaceuticals
Eli Lilly
Jiangsu Hengrui Pharmaceuticals
Curis Inc.
Bristol-Myers Squibb
Junshi Biosciences
Innovent Biologics
BeiGene
Segment by Type
Toripalimab
Camrelizumab
Atezolizumab
Tislelizumab
Nivolumab
Others
Segment by Application
Melanoma Treatment
Non-Small Cell Lung Cancer Treatment
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Tumor Immunity PD-1 Inhibitors report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 Tumor Immunity PD-1 Inhibitors Market Overview
1.1 Product Overview and Scope of Tumor Immunity PD-1 Inhibitors
1.2 Tumor Immunity PD-1 Inhibitors Segment by Type
1.2.1 Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Type (2023-2029)
1.2.2 Toripalimab
1.2.3 Camrelizumab
1.2.4 Atezolizumab
1.2.5 Tislelizumab
1.2.6 Nivolumab
1.2.7 Others
1.3 Tumor Immunity PD-1 Inhibitors Segment by Application
1.3.1 Global Tumor Immunity PD-1 Inhibitors Market Value by Application: (2023-2029)
1.3.2 Melanoma Treatment
1.3.3 Non-Small Cell Lung Cancer Treatment
1.3.4 Others
1.4 Global Tumor Immunity PD-1 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Tumor Immunity PD-1 Inhibitors Revenue 2018-2029
1.4.2 Global Tumor Immunity PD-1 Inhibitors Sales 2018-2029
1.4.3 Global Tumor Immunity PD-1 Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Tumor Immunity PD-1 Inhibitors Market Competition by Manufacturers
2.1 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Manufacturers (2018-2023)
2.2 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Tumor Immunity PD-1 Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global Tumor Immunity PD-1 Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Product Type & Application
2.7 Tumor Immunity PD-1 Inhibitors Market Competitive Situation and Trends
2.7.1 Tumor Immunity PD-1 Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tumor Immunity PD-1 Inhibitors Players Market Share by Revenue
2.7.3 Global Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tumor Immunity PD-1 Inhibitors Retrospective Market Scenario by Region
3.1 Global Tumor Immunity PD-1 Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Tumor Immunity PD-1 Inhibitors Global Tumor Immunity PD-1 Inhibitors Sales by Region: 2018-2029
3.2.1 Global Tumor Immunity PD-1 Inhibitors Sales by Region: 2018-2023
3.2.2 Global Tumor Immunity PD-1 Inhibitors Sales by Region: 2024-2029
3.3 Global Tumor Immunity PD-1 Inhibitors Global Tumor Immunity PD-1 Inhibitors Revenue by Region: 2018-2029
3.3.1 Global Tumor Immunity PD-1 Inhibitors Revenue by Region: 2018-2023
3.3.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Region: 2024-2029
3.4 North America Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country
3.4.1 North America Tumor Immunity PD-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2029)
3.4.3 North America Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country
3.5.1 Europe Tumor Immunity PD-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2029)
3.5.3 Europe Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Tumor Immunity PD-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumor Immunity PD-1 Inhibitors Sales by Type (2018-2029)
4.1.1 Global Tumor Immunity PD-1 Inhibitors Sales by Type (2018-2023)
4.1.2 Global Tumor Immunity PD-1 Inhibitors Sales by Type (2024-2029)
4.1.3 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Type (2018-2029)
4.2.1 Global Tumor Immunity PD-1 Inhibitors Revenue by Type (2018-2023)
4.2.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Type (2024-2029)
4.2.3 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global Tumor Immunity PD-1 Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global Tumor Immunity PD-1 Inhibitors Sales by Application (2018-2029)
5.1.1 Global Tumor Immunity PD-1 Inhibitors Sales by Application (2018-2023)
5.1.2 Global Tumor Immunity PD-1 Inhibitors Sales by Application (2024-2029)
5.1.3 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Application (2018-2029)
5.2.1 Global Tumor Immunity PD-1 Inhibitors Revenue by Application (2018-2023)
5.2.2 Global Tumor Immunity PD-1 Inhibitors Revenue by Application (2024-2029)
5.2.3 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global Tumor Immunity PD-1 Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Tumor Immunity PD-1 Inhibitors Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Tumor Immunity PD-1 Inhibitors Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Sumitomo Dainippon Pharma
6.3.1 Sumitomo Dainippon Pharma Corporation Information
6.3.2 Sumitomo Dainippon Pharma Description and Business Overview
6.3.3 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Portfolio
6.3.5 Sumitomo Dainippon Pharma Recent Developments/Updates
6.4 Genentech (Roche)
6.4.1 Genentech (Roche) Corporation Information
6.4.2 Genentech (Roche) Description and Business Overview
6.4.3 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Portfolio
6.4.5 Genentech (Roche) Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.5.4 AstraZeneca Tumor Immunity PD-1 Inhibitors Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Pfizer Tumor Immunity PD-1 Inhibitors Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GSK Tumor Immunity PD-1 Inhibitors Product Portfolio
6.7.5 GSK Recent Developments/Updates
6.8 Regeneron Pharmaceuticals
6.8.1 Regeneron Pharmaceuticals Corporation Information
6.8.2 Regeneron Pharmaceuticals Description and Business Overview
6.8.3 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Portfolio
6.8.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Eli Lilly Tumor Immunity PD-1 Inhibitors Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Jiangsu Hengrui Pharmaceuticals
6.10.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
6.10.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.10.3 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Portfolio
6.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.11 Curis Inc.
6.11.1 Curis Inc. Corporation Information
6.11.2 Curis Inc. Tumor Immunity PD-1 Inhibitors Description and Business Overview
6.11.3 Curis Inc. Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Curis Inc. Tumor Immunity PD-1 Inhibitors Product Portfolio
6.11.5 Curis Inc. Recent Developments/Updates
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Corporation Information
6.12.2 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Description and Business Overview
6.12.3 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments/Updates
6.13 Junshi Biosciences
6.13.1 Junshi Biosciences Corporation Information
6.13.2 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Description and Business Overview
6.13.3 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Portfolio
6.13.5 Junshi Biosciences Recent Developments/Updates
6.14 Innovent Biologics
6.14.1 Innovent Biologics Corporation Information
6.14.2 Innovent Biologics Tumor Immunity PD-1 Inhibitors Description and Business Overview
6.14.3 Innovent Biologics Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Portfolio
6.14.5 Innovent Biologics Recent Developments/Updates
6.15 BeiGene
6.15.1 BeiGene Corporation Information
6.15.2 BeiGene Tumor Immunity PD-1 Inhibitors Description and Business Overview
6.15.3 BeiGene Tumor Immunity PD-1 Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.15.4 BeiGene Tumor Immunity PD-1 Inhibitors Product Portfolio
6.15.5 BeiGene Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumor Immunity PD-1 Inhibitors Industry Chain Analysis
7.2 Tumor Immunity PD-1 Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumor Immunity PD-1 Inhibitors Production Mode & Process
7.4 Tumor Immunity PD-1 Inhibitors Sales and Marketing
7.4.1 Tumor Immunity PD-1 Inhibitors Sales Channels
7.4.2 Tumor Immunity PD-1 Inhibitors Distributors
7.5 Tumor Immunity PD-1 Inhibitors Customers
8 Tumor Immunity PD-1 Inhibitors Market Dynamics
8.1 Tumor Immunity PD-1 Inhibitors Industry Trends
8.2 Tumor Immunity PD-1 Inhibitors Market Drivers
8.3 Tumor Immunity PD-1 Inhibitors Market Challenges
8.4 Tumor Immunity PD-1 Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Tumor Immunity PD-1 Inhibitors Market Competitive Situation by Manufacturers in 2022
Table 4. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Tumor Immunity PD-1 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Tumor Immunity PD-1 Inhibitors, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Tumor Immunity PD-1 Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tumor Immunity PD-1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity PD-1 Inhibitors as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Tumor Immunity PD-1 Inhibitors Sales by Region (2018-2023) & (K Units)
Table 18. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2018-2023)
Table 19. Global Tumor Immunity PD-1 Inhibitors Sales by Region (2024-2029) & (K Units)
Table 20. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2024-2029)
Table 21. Global Tumor Immunity PD-1 Inhibitors Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2018-2023)
Table 23. Global Tumor Immunity PD-1 Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2024-2029)
Table 25. North America Tumor Immunity PD-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2023) & (K Units)
Table 27. North America Tumor Immunity PD-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 28. North America Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Tumor Immunity PD-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Tumor Immunity PD-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2023) & (K Units)
Table 32. Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 33. Europe Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Tumor Immunity PD-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Tumor Immunity PD-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Tumor Immunity PD-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Tumor Immunity PD-1 Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Tumor Immunity PD-1 Inhibitors Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Tumor Immunity PD-1 Inhibitors Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Tumor Immunity PD-1 Inhibitors Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Tumor Immunity PD-1 Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Type (2018-2023)
Table 51. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Type (2024-2029)
Table 52. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2018-2023)
Table 53. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2024-2029)
Table 54. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Type (2018-2023)
Table 57. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Type (2024-2029)
Table 58. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Type (2018-2023)
Table 59. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Type (2024-2029)
Table 60. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Application (2018-2023)
Table 61. Global Tumor Immunity PD-1 Inhibitors Sales (K Units) by Application (2024-2029)
Table 62. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2018-2023)
Table 63. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2024-2029)
Table 64. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Application (2018-2023)
Table 67. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Application (2024-2029)
Table 68. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Application (2018-2023)
Table 69. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Merck Tumor Immunity PD-1 Inhibitors Product
Table 74. Merck Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Novartis Tumor Immunity PD-1 Inhibitors Product
Table 79. Novartis Recent Developments/Updates
Table 80. Sumitomo Dainippon Pharma Corporation Information
Table 81. Sumitomo Dainippon Pharma Description and Business Overview
Table 82. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product
Table 84. Sumitomo Dainippon Pharma Recent Developments/Updates
Table 85. Genentech (Roche) Corporation Information
Table 86. Genentech (Roche) Description and Business Overview
Table 87. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product
Table 89. Genentech (Roche) Recent Developments/Updates
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. AstraZeneca Tumor Immunity PD-1 Inhibitors Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Pfizer Tumor Immunity PD-1 Inhibitors Product
Table 99. Pfizer Recent Developments/Updates
Table 100. GSK Corporation Information
Table 101. GSK Description and Business Overview
Table 102. GSK Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. GSK Tumor Immunity PD-1 Inhibitors Product
Table 104. GSK Recent Developments/Updates
Table 105. Regeneron Pharmaceuticals Corporation Information
Table 106. Regeneron Pharmaceuticals Description and Business Overview
Table 107. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product
Table 109. Regeneron Pharmaceuticals Recent Developments/Updates
Table 110. Eli Lilly Corporation Information
Table 111. Eli Lilly Description and Business Overview
Table 112. Eli Lilly Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Eli Lilly Tumor Immunity PD-1 Inhibitors Product
Table 114. Eli Lilly Recent Developments/Updates
Table 115. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 116. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 117. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product
Table 119. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 120. Curis Inc. Corporation Information
Table 121. Curis Inc. Description and Business Overview
Table 122. Curis Inc. Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Curis Inc. Tumor Immunity PD-1 Inhibitors Product
Table 124. Curis Inc. Recent Developments/Updates
Table 125. Bristol-Myers Squibb Corporation Information
Table 126. Bristol-Myers Squibb Description and Business Overview
Table 127. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product
Table 129. Bristol-Myers Squibb Recent Developments/Updates
Table 130. Junshi Biosciences Corporation Information
Table 131. Junshi Biosciences Description and Business Overview
Table 132. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product
Table 134. Junshi Biosciences Recent Developments/Updates
Table 135. Innovent Biologics Corporation Information
Table 136. Innovent Biologics Description and Business Overview
Table 137. Innovent Biologics Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Innovent Biologics Tumor Immunity PD-1 Inhibitors Product
Table 139. Innovent Biologics Recent Developments/Updates
Table 140. BeiGene Corporation Information
Table 141. BeiGene Description and Business Overview
Table 142. BeiGene Tumor Immunity PD-1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. BeiGene Tumor Immunity PD-1 Inhibitors Product
Table 144. BeiGene Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Tumor Immunity PD-1 Inhibitors Distributors List
Table 148. Tumor Immunity PD-1 Inhibitors Customers List
Table 149. Tumor Immunity PD-1 Inhibitors Market Trends
Table 150. Tumor Immunity PD-1 Inhibitors Market Drivers
Table 151. Tumor Immunity PD-1 Inhibitors Market Challenges
Table 152. Tumor Immunity PD-1 Inhibitors Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Tumor Immunity PD-1 Inhibitors
Figure 2. Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Tumor Immunity PD-1 Inhibitors Market Share by Type in 2022 & 2029
Figure 4. Toripalimab Product Picture
Figure 5. Camrelizumab Product Picture
Figure 6. Atezolizumab Product Picture
Figure 7. Tislelizumab Product Picture
Figure 8. Nivolumab Product Picture
Figure 9. Others Product Picture
Figure 10. Global Tumor Immunity PD-1 Inhibitors Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 11. Global Tumor Immunity PD-1 Inhibitors Market Share by Application in 2022 & 2029
Figure 12. Melanoma Treatment
Figure 13. Non-Small Cell Lung Cancer Treatment
Figure 14. Others
Figure 15. Global Tumor Immunity PD-1 Inhibitors Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Tumor Immunity PD-1 Inhibitors Market Size (2018-2029) & (US$ Million)
Figure 17. Global Tumor Immunity PD-1 Inhibitors Sales (2018-2029) & (K Units)
Figure 18. Global Tumor Immunity PD-1 Inhibitors Average Price (US$/Unit) & (2018-2029)
Figure 19. Tumor Immunity PD-1 Inhibitors Report Years Considered
Figure 20. Tumor Immunity PD-1 Inhibitors Sales Share by Manufacturers in 2022
Figure 21. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Tumor Immunity PD-1 Inhibitors Players: Market Share by Revenue in 2022
Figure 23. Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 25. North America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 26. North America Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 27. United States Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 30. Europe Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 31. Germany Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2018-2029)
Figure 37. Asia Pacific Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2018-2029)
Figure 38. China Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Japan Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. South Korea Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. India Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Australia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. China Taiwan Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 46. Latin America Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Tumor Immunity PD-1 Inhibitors Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Tumor Immunity PD-1 Inhibitors Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE Tumor Immunity PD-1 Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Tumor Immunity PD-1 Inhibitors by Type (2018-2029)
Figure 56. Global Revenue Market Share of Tumor Immunity PD-1 Inhibitors by Type (2018-2029)
Figure 57. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Tumor Immunity PD-1 Inhibitors by Application (2018-2029)
Figure 59. Global Revenue Market Share of Tumor Immunity PD-1 Inhibitors by Application (2018-2029)
Figure 60. Global Tumor Immunity PD-1 Inhibitors Price (US$/Unit) by Application (2018-2029)
Figure 61. Tumor Immunity PD-1 Inhibitors Value Chain
Figure 62. Tumor Immunity PD-1 Inhibitors Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies